Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > REGULATORY
REGULATORY
- Shock, Anaphylaxis Added to Xofluza’s ADR List; Label Changes for Checkpoint Blockers
June 5, 2019
- MHLW Panel Approves to Contraindicate Metformin in Impaired Kidney Function Patients with eGFR less than 30
June 4, 2019
- Reborn PMDA Boots Up under New Skipper, Bolstering “Patient First” Initiatives
June 4, 2019
- Kampo Industry Expresses Concerns over Copay Hikes, Narrow Definition of Essential Drugs: LDP League
June 3, 2019
- Bayer’s Larotrectinib, Novartis’ Capmatinib Get Orphan Status in Japan
June 3, 2019
- June Approval Likely for Chugai’s NTRK-Gene Targeting Entrectinib, 2nd Tumor-Agnostic Drug
May 31, 2019
- LDP Junior Politicians Set Up Vaccine Study Group
May 31, 2019
- “Drugs for Specific Use” Might Include NTD Medicines: MHLW Official
May 30, 2019
- Chuikyo Subcommittee Agrees on Discussion Timeline, Topics for 2020 Drug Pricing Reform
May 30, 2019
- MHLW Panel OKs Public Knowledge-Based Applications for Add’l Indication for Rituxan
May 30, 2019
- Japan Approves Health Coverage for Cancer Gene Panel Tests
May 30, 2019
- Alnylam’s RNAi Drug Now in Line for Japan Approval in June
May 29, 2019
- Japan’s 2nd Enbrel Biosimilar, Pfizer’s Herceptin Follow-On Get Listing
May 28, 2019
- Quizartinib Added to List of MHLW Panel Review on May 30
May 24, 2019
- LDP’s Life Science Study Group Eyes Enhancement of Databases, AMED Functions
May 23, 2019
- MHLW Approves Entyvio’s Crohn’s Disease Indication and More
May 23, 2019
- JPMA Prods Revamp of PMP, Launch Premiums, Comparator Selection Criteria towards 2020 Reform
May 22, 2019
- Minister Says Kymriah Pricing Appropriate Even with Low Cost Disclosure Ratio
May 22, 2019
- MHLW Planning to Launch Report System on Inappropriate Detailing Activity as Early as Summer
May 21, 2019
- Govt, Industry Share Views on Challenges in Data Use, Drug Pricing
May 21, 2019
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…